Effect of L-carnitine on control of asthmatic patients

L-carnitine effect of controlling the asthmathic patients, a triple blind randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016112331057N1

Enrollment

Registered

2016-12-24

Start date

2016-09-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: Intervention group recieved 2 grams of oral L-carnitine syrup twice daily for 12 weeks. Intervention 2: The control group received placebo twice daily for 12 weeks.

Treatment - Drugs

Placebo

Intervention group recieved 2 grams of oral L-carnitine syrup twice daily for 12 weeks

The control group received placebo twice daily for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-Known asthmatic patients 2-New patients with symptoms of asthma and confirmed with spirometery 3-Age between 18 and 80 years Exclusion criteria: 1-Smoking 2-Chronic respiratory disease (except asthma) 3-Chronic marked systemic disease 4-Pnemonia in last momth 5-Drugs affect l-carnitine level(ex:anticonvulsant) 6-Adverse effect of l-carnitine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Spirometery Parameters (FEV1,FEV1/FVC). Timepoint: Before and 12 weeks after intervention. Method of measurement: Spirometery device.;Daily attack of asthma (need to use bronchodilator spray). Timepoint: Before and 12 weeks after intervention. Method of measurement: Interview.;Overnight attack of asthma (need to use bronchodilator spray). Timepoint: Before and 12 weeks after intervention. Method of measurement: Interview.;Emergency care refer. Timepoint: Before and 12 weeks after intervention. Method of measurement: Interview.;Asthma control degree. Timepoint: Before and 4,8 and 12 weeks after intervention. Method of measurement: ACT(Asthma Control Test) Questionnaire.	—

Measure

Time frame

Spirometery Parameters (FEV1,FEV1/FVC). Timepoint: Before and 12 weeks after intervention. Method of measurement: Spirometery device.;Daily attack of asthma (need to use bronchodilator spray). Timepoint: Before and 12 weeks after intervention. Method of measurement: Interview.;Overnight attack of asthma (need to use bronchodilator spray). Timepoint: Before and 12 weeks after intervention. Method of measurement: Interview.;Emergency care refer. Timepoint: Before and 12 weeks after intervention. Method of measurement: Interview.;Asthma control degree. Timepoint: Before and 4,8 and 12 weeks after intervention. Method of measurement: ACT(Asthma Control Test) Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Ramezanian Nik

Hormozgan University of Medical Sciences

ehsan.nick@gmail.com+98 76 3562 3208

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026